|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Type** | **Subtype** | Prevalence | Radiographic Appearance | Histologic Morphology | Notable Features | Histology Images | Clinical Images |
| **Intramedullary** |  |  |  |  |  |  |  |
|  | **Conventional** | >80% | * Permeative lesion with varying degrees of osteolysis and osseous matrix * Cortical destruction, soft tissue extension * Sunburst periosteal reaction, Codman’s triangle * Lytic pattern may predominate in older patients13 | Severe anaplasia, pleomorphism, frequent mitoses, immature osteoid matrix, varying degrees of additional types of extracellular matrix determine the histologic variant   1. **Osteoblastic**: 75% of cases12 2. **Chondroblastic**:defined by at least 30% chondroid matrix composition, 16% of cases15 3. **Fibroblastic**: defined by dominant collagen matrix with a storiform pattern, 10% of cases7,12 4. **Others**: includes giant-cell rich, osteoblastoma-like, epithelioid, clear cell, chondroblastoma-like12 |  | Figure 1 Supplemental Digital Content | Figure 2 Supplemental Digital Content |
|  | **Telangiectatic** | 4-8%14, 16 | * Eccentric with cortical expansion * Predominantly lytic * MRI demonstrates a soft tissue mass, areas of hemorrhage, peripheral, septal and nodular enhancement with contrast17 | Blood filled spaces separated by septae with pleomorphic, malignant cells. Osteoid may be less apparent or absent on biopsy samples | * Diagnosis may be difficult given radiographic resemblance to aneurysmal bone cysts * Pathologic fracture is common (~30%)14 | Figure 3 Supplemental Digital Content | Figures 4 and 5 Supplemental Digital Content |
|  | **Small** **Cell** | 1% | * Permeative lesion with variable amounts of intramedullary sclerosis * Mineralization may be absent/minimal | Small, round malignant cells with varying amounts of osteoid production | Distinguished from Ewing sarcoma by the lack of nuclear spindling and the FLI-1 translocation18 |  |  |
|  | **Low Grade Central** | 1-2% | * Mixed sclerotic/lytic lesion with a geographic border * Cortical erosion and an extraosseous soft tissue mass, seen more readily with MRI | Hypocellular spindle tumor with minimal cytologic atypia with a permeative growth pattern within the surrounding normal bone | Overexpression of CDK4 and MDM2 helps differentiate from benign fibro-osseous lesions19 | Figure 6 Supplemental Digital Content | Figure 7 Supplemental Digital Content |
| **Surface** |  |  |  |  |  |  |  |
|  | **Parosteal** | 4%20 | * Well-mineralized cortically based mass * Medullary involvement is present in 35% of cases20 | Spindle cells with variable amounts of trabecular bone and cartilage | * Posterior distal femur is the classic location * Overexpression of CDK4 and MDM221 * Dedifferentiated parosteal osteosarcoma can develop in approximately 25%21 | Figure 6 Supplemental Digital Content | Figures 8 and 9 Supplemental Digital Content |
|  | **Periosteal** | < 2%22 | * Broad-based tumor on the surface of the diaphysis * Cortical thickening and scalloping, periosteal reaction, soft tissue mineralization23 | Areas of atypical cartilage with focal areas of intermediate osteosarcoma arising beneath the periosteum | * Diaphyseal location * Role of chemotherapy is controversial * Overall survival superior to conventional osteosarcoma | Figure 10 Supplemental Digital Content | Figures 11-13 Supplemental Digital Content |
|  | **High-Grade Surface** | < 1% | * Radiographically may resemble parosteal or periosteal osteosarcoma, but with more aggressive features * Medullary involvement present in approximately 50% of cases24 | Surface based lesion that histologically resembles high-grade, intramedullary conventional osteosarcoma with pleomorphic cells producing osteoid. May have histologic variants, including osteoblastic or chondroblastic | Treated like conventional, intramedullary osteosarcoma |  | Figure 14 Supplemental Digital Content |

7. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. *Cancer* 2006;106:1154-1161.

12. Fletcher CDM, World Health Organization., International Agency for Research on Cancer.: *WHO classification of tumours of soft tissue and bone*. ed 4th. Lyon: IARC Press, 2013, p 468 p.

13. Song WS, Kong CB, Jeon DG, et al.: Prognosis of extremity osteosarcoma in patients aged 40-60 years: a cohort/case controlled study at a single institute. *Eur J Surg Oncol* 2010;36:483-488.

14. Angelini A, Mavrogenis AF, Trovarelli G, Ferrari S, Picci P, Ruggieri P: Telangiectatic osteosarcoma: a review of 87 cases. *J Cancer Res Clin Oncol* 2016;142:2197-2207.

15. Tsagozis P, Laitinen MK, Stevenson JD, Jeys LM, Abudu A, Parry MC: Treatment outcome of patients with chondroblastic osteosarcoma of the limbs and pelvis. *Bone Joint J* 2019;101-B:739-744.

16. Smeland S, Bielack SS, Whelan J, et al.: Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort. *Eur J Cancer* 2019;109:36-50.

17. Murphey MD, wan Jaovisidha S, Temple HT, Gannon FH, Jelinek JS, Malawer MM: Telangiectatic osteosarcoma: radiologic-pathologic comparison. *Radiology* 2003;229:545-553.

18. Lee AF, Hayes MM, Lebrun D, et al.: FLI-1 distinguishes Ewing sarcoma from small cell osteosarcoma and mesenchymal chondrosarcoma. *Appl Immunohistochem Mol Morphol* 2011;19:233-238.

19. Yoshida A, Ushiku T, Motoi T, et al.: Immunohistochemical analysis of MDM2 and CDK4 distinguishes low-grade osteosarcoma from benign mimics. *Mod Pathol* 2010;23:1279-1288.

20. Funovics PT, Bucher F, Toma CD, Kotz RI, Dominkus M: Treatment and outcome of parosteal osteosarcoma: biological versus endoprosthetic reconstruction. *J Surg Oncol* 2011;103:782-789.

21. Ruengwanichayakun P, Gambarotti M, Frisoni T, et al.: Parosteal osteosarcoma: a monocentric retrospective analysis of 195 patients. *Hum Pathol* 2019;91:11-18.

22. Cesari M, Alberghini M, Vanel D, et al.: Periosteal osteosarcoma: a single-institution experience. *Cancer* 2011;117:1731-1735.

23. Murphey MD, Jelinek JS, Temple HT, Flemming DJ, Gannon FH: Imaging of periosteal osteosarcoma: radiologic-pathologic comparison. *Radiology* 2004;233:129-138.

24. Staals EL, Bacchini P, Bertoni F: High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute. *Cancer* 2008;112:1592-1599.